CA2718549C - In vivo temporal control of activatable matrix-degrading enzymes - Google Patents
In vivo temporal control of activatable matrix-degrading enzymes Download PDFInfo
- Publication number
- CA2718549C CA2718549C CA2718549A CA2718549A CA2718549C CA 2718549 C CA2718549 C CA 2718549C CA 2718549 A CA2718549 A CA 2718549A CA 2718549 A CA2718549 A CA 2718549A CA 2718549 C CA2718549 C CA 2718549C
- Authority
- CA
- Canada
- Prior art keywords
- cathepsin
- enzyme
- ecm
- sequence
- activator
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 102000036444 extracellular matrix enzymes Human genes 0.000 title abstract description 121
- 108091007167 extracellular matrix enzymes Proteins 0.000 title abstract description 121
- 238000001727 in vivo Methods 0.000 title abstract description 38
- 230000002123 temporal effect Effects 0.000 title description 15
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims abstract description 205
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims abstract description 205
- 210000002744 extracellular matrix Anatomy 0.000 claims abstract description 201
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 90
- 201000010099 disease Diseases 0.000 claims abstract description 84
- 230000001404 mediated effect Effects 0.000 claims abstract description 41
- 102000004190 Enzymes Human genes 0.000 claims description 381
- 108090000790 Enzymes Proteins 0.000 claims description 381
- 230000000694 effects Effects 0.000 claims description 157
- 239000012190 activator Substances 0.000 claims description 138
- 235000001014 amino acid Nutrition 0.000 claims description 134
- 150000001413 amino acids Chemical class 0.000 claims description 126
- 230000003213 activating effect Effects 0.000 claims description 115
- 102000008186 Collagen Human genes 0.000 claims description 109
- 108010035532 Collagen Proteins 0.000 claims description 109
- 239000000203 mixture Substances 0.000 claims description 108
- 229920001436 collagen Polymers 0.000 claims description 107
- 108090000623 proteins and genes Proteins 0.000 claims description 90
- 230000002378 acidificating effect Effects 0.000 claims description 85
- 102000004169 proteins and genes Human genes 0.000 claims description 72
- 108090000624 Cathepsin L Proteins 0.000 claims description 70
- 230000002132 lysosomal effect Effects 0.000 claims description 69
- 235000018102 proteins Nutrition 0.000 claims description 68
- 239000000872 buffer Substances 0.000 claims description 61
- 108010062466 Enzyme Precursors Proteins 0.000 claims description 56
- 102000010911 Enzyme Precursors Human genes 0.000 claims description 56
- 102000005600 Cathepsins Human genes 0.000 claims description 47
- 108010084457 Cathepsins Proteins 0.000 claims description 47
- 210000001519 tissue Anatomy 0.000 claims description 41
- 108010067306 Fibronectins Proteins 0.000 claims description 40
- 102000016359 Fibronectins Human genes 0.000 claims description 40
- 230000007935 neutral effect Effects 0.000 claims description 37
- 230000002255 enzymatic effect Effects 0.000 claims description 34
- 102000016942 Elastin Human genes 0.000 claims description 29
- 108010014258 Elastin Proteins 0.000 claims description 29
- 229920002549 elastin Polymers 0.000 claims description 29
- 238000011282 treatment Methods 0.000 claims description 27
- 239000002253 acid Substances 0.000 claims description 23
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 21
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 21
- 102000012422 Collagen Type I Human genes 0.000 claims description 20
- 108010022452 Collagen Type I Proteins 0.000 claims description 19
- 102000005927 Cysteine Proteases Human genes 0.000 claims description 19
- 108010005843 Cysteine Proteases Proteins 0.000 claims description 19
- 108010037536 heparanase Proteins 0.000 claims description 18
- 102100024025 Heparanase Human genes 0.000 claims description 17
- 208000032544 Cicatrix Diseases 0.000 claims description 15
- 231100000241 scar Toxicity 0.000 claims description 15
- 230000037387 scars Effects 0.000 claims description 15
- 239000000243 solution Substances 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- 235000004252 protein component Nutrition 0.000 claims description 11
- 102000035101 Aspartic proteases Human genes 0.000 claims description 10
- 108091005502 Aspartic proteases Proteins 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 10
- 208000035484 Cellulite Diseases 0.000 claims description 9
- 102000004266 Collagen Type IV Human genes 0.000 claims description 9
- 108010042086 Collagen Type IV Proteins 0.000 claims description 9
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 9
- 206010049752 Peau d'orange Diseases 0.000 claims description 9
- 230000036232 cellulite Effects 0.000 claims description 9
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 9
- 238000007920 subcutaneous administration Methods 0.000 claims description 9
- 102100024940 Cathepsin K Human genes 0.000 claims description 8
- 229910019142 PO4 Inorganic materials 0.000 claims description 8
- 238000009472 formulation Methods 0.000 claims description 8
- 238000007918 intramuscular administration Methods 0.000 claims description 8
- 239000010452 phosphate Substances 0.000 claims description 8
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 8
- SXGZJKUKBWWHRA-UHFFFAOYSA-N 2-(N-morpholiniumyl)ethanesulfonate Chemical compound [O-]S(=O)(=O)CC[NH+]1CCOCC1 SXGZJKUKBWWHRA-UHFFFAOYSA-N 0.000 claims description 7
- 239000000725 suspension Substances 0.000 claims description 7
- 108090000613 Cathepsin S Proteins 0.000 claims description 6
- 208000002260 Keloid Diseases 0.000 claims description 6
- 206010025282 Lymphoedema Diseases 0.000 claims description 6
- 208000004362 Penile Induration Diseases 0.000 claims description 6
- 208000020758 Peyronie disease Diseases 0.000 claims description 6
- 208000002502 lymphedema Diseases 0.000 claims description 6
- 102000003902 Cathepsin C Human genes 0.000 claims description 5
- 108090000267 Cathepsin C Proteins 0.000 claims description 5
- 102000003908 Cathepsin D Human genes 0.000 claims description 5
- 108090000258 Cathepsin D Proteins 0.000 claims description 5
- 102000004176 Cathepsin F Human genes 0.000 claims description 5
- 108090000610 Cathepsin F Proteins 0.000 claims description 5
- 108090000625 Cathepsin K Proteins 0.000 claims description 5
- 102100035654 Cathepsin S Human genes 0.000 claims description 5
- 239000008366 buffered solution Substances 0.000 claims description 5
- 230000001969 hypertrophic effect Effects 0.000 claims description 5
- 210000001117 keloid Anatomy 0.000 claims description 5
- 102000004225 Cathepsin B Human genes 0.000 claims description 4
- 108090000712 Cathepsin B Proteins 0.000 claims description 4
- 102000004178 Cathepsin E Human genes 0.000 claims description 4
- 108090000611 Cathepsin E Proteins 0.000 claims description 4
- 102000004175 Cathepsin H Human genes 0.000 claims description 4
- 108090000619 Cathepsin H Proteins 0.000 claims description 4
- 102100026540 Cathepsin L2 Human genes 0.000 claims description 4
- 102000011933 Cathepsin W Human genes 0.000 claims description 4
- 108010061112 Cathepsin W Proteins 0.000 claims description 4
- 102000001187 Collagen Type III Human genes 0.000 claims description 4
- 108010069502 Collagen Type III Proteins 0.000 claims description 4
- 208000001708 Dupuytren contracture Diseases 0.000 claims description 4
- 101000983577 Homo sapiens Cathepsin L2 Proteins 0.000 claims description 4
- 206010023230 Joint stiffness Diseases 0.000 claims description 4
- 208000031737 Tissue Adhesions Diseases 0.000 claims description 4
- 230000000994 depressogenic effect Effects 0.000 claims description 4
- 239000006193 liquid solution Substances 0.000 claims description 4
- 239000006194 liquid suspension Substances 0.000 claims description 4
- 108010009405 ribosomal neutral proteinase Proteins 0.000 claims description 4
- 102000000503 Collagen Type II Human genes 0.000 claims description 3
- 108010041390 Collagen Type II Proteins 0.000 claims description 3
- 206010016654 Fibrosis Diseases 0.000 claims description 3
- 206010034464 Periarthritis Diseases 0.000 claims description 3
- 206010039710 Scleroderma Diseases 0.000 claims description 3
- 208000008609 collagenous colitis Diseases 0.000 claims description 3
- 230000004761 fibrosis Effects 0.000 claims description 3
- 201000010603 frozen shoulder Diseases 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 239000007924 injection Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 102000004172 Cathepsin L Human genes 0.000 claims 16
- 101710177066 Cathepsin O Proteins 0.000 claims 2
- 230000004913 activation Effects 0.000 abstract description 118
- 238000000034 method Methods 0.000 abstract description 72
- 230000001965 increasing effect Effects 0.000 abstract description 14
- 230000009471 action Effects 0.000 abstract description 8
- 238000009825 accumulation Methods 0.000 abstract description 6
- 230000008021 deposition Effects 0.000 abstract description 6
- 208000035475 disorder Diseases 0.000 abstract description 6
- 229940088598 enzyme Drugs 0.000 description 339
- 229940024606 amino acid Drugs 0.000 description 110
- 108090000765 processed proteins & peptides Proteins 0.000 description 107
- 102000004196 processed proteins & peptides Human genes 0.000 description 89
- 229920001184 polypeptide Polymers 0.000 description 86
- 102000035195 Peptidases Human genes 0.000 description 67
- 108091005804 Peptidases Proteins 0.000 description 67
- 239000000758 substrate Substances 0.000 description 64
- 239000004365 Protease Substances 0.000 description 62
- 102100026534 Procathepsin L Human genes 0.000 description 55
- 210000003491 skin Anatomy 0.000 description 48
- 108010067787 Proteoglycans Proteins 0.000 description 47
- 210000004027 cell Anatomy 0.000 description 47
- 102000016611 Proteoglycans Human genes 0.000 description 46
- 238000003776 cleavage reaction Methods 0.000 description 39
- 230000007017 scission Effects 0.000 description 39
- 150000007523 nucleic acids Chemical class 0.000 description 35
- 239000003795 chemical substances by application Substances 0.000 description 34
- 102000039446 nucleic acids Human genes 0.000 description 33
- 108020004707 nucleic acids Proteins 0.000 description 33
- 230000003197 catalytic effect Effects 0.000 description 28
- 229910021645 metal ion Inorganic materials 0.000 description 27
- 241000894007 species Species 0.000 description 27
- 229920002674 hyaluronan Polymers 0.000 description 25
- 235000019419 proteases Nutrition 0.000 description 25
- 239000003638 chemical reducing agent Substances 0.000 description 24
- 235000018417 cysteine Nutrition 0.000 description 24
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 24
- 230000004048 modification Effects 0.000 description 23
- 238000012986 modification Methods 0.000 description 23
- 108010003272 Hyaluronate lyase Proteins 0.000 description 22
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 22
- 102000012479 Serine Proteases Human genes 0.000 description 22
- 108010022999 Serine Proteases Proteins 0.000 description 22
- 102000009066 Hyaluronoglucosaminidase Human genes 0.000 description 21
- 229960002773 hyaluronidase Drugs 0.000 description 21
- 239000010410 layer Substances 0.000 description 21
- 239000011159 matrix material Substances 0.000 description 21
- 239000002243 precursor Substances 0.000 description 21
- 108010010803 Gelatin Proteins 0.000 description 20
- 229920000159 gelatin Polymers 0.000 description 20
- 235000019322 gelatine Nutrition 0.000 description 20
- 235000011852 gelatine desserts Nutrition 0.000 description 20
- 238000006243 chemical reaction Methods 0.000 description 19
- 239000008273 gelatin Substances 0.000 description 19
- 229920002683 Glycosaminoglycan Polymers 0.000 description 18
- 239000011575 calcium Substances 0.000 description 18
- 239000002773 nucleotide Substances 0.000 description 18
- 125000003729 nucleotide group Chemical group 0.000 description 18
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 17
- 108020004414 DNA Proteins 0.000 description 17
- 125000003275 alpha amino acid group Chemical group 0.000 description 17
- 229910052791 calcium Inorganic materials 0.000 description 17
- 230000006870 function Effects 0.000 description 17
- 108010085895 Laminin Proteins 0.000 description 16
- 102000007547 Laminin Human genes 0.000 description 16
- 102000005741 Metalloproteases Human genes 0.000 description 16
- 108010006035 Metalloproteases Proteins 0.000 description 16
- 210000002808 connective tissue Anatomy 0.000 description 16
- 238000012545 processing Methods 0.000 description 16
- 230000027455 binding Effects 0.000 description 15
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical group CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 15
- 229940099552 hyaluronan Drugs 0.000 description 15
- 239000000126 substance Substances 0.000 description 15
- 229920002971 Heparan sulfate Polymers 0.000 description 14
- 102000001974 Hyaluronidases Human genes 0.000 description 14
- 108050009363 Hyaluronidases Proteins 0.000 description 14
- -1 include for example Proteins 0.000 description 14
- 230000002441 reversible effect Effects 0.000 description 14
- 230000008859 change Effects 0.000 description 13
- 150000001875 compounds Chemical class 0.000 description 13
- 102000003886 Glycoproteins Human genes 0.000 description 12
- 108090000288 Glycoproteins Proteins 0.000 description 12
- 238000003556 assay Methods 0.000 description 12
- 230000015556 catabolic process Effects 0.000 description 12
- 210000004207 dermis Anatomy 0.000 description 12
- 238000000338 in vitro Methods 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 12
- 239000007788 liquid Substances 0.000 description 11
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 10
- 108010032088 Calpain Proteins 0.000 description 10
- 102000007590 Calpain Human genes 0.000 description 10
- 125000000539 amino acid group Chemical group 0.000 description 10
- 238000006731 degradation reaction Methods 0.000 description 10
- 230000000593 degrading effect Effects 0.000 description 10
- 229960003160 hyaluronic acid Drugs 0.000 description 10
- 230000007246 mechanism Effects 0.000 description 10
- 230000001105 regulatory effect Effects 0.000 description 10
- 238000006467 substitution reaction Methods 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 229910001868 water Inorganic materials 0.000 description 10
- 241000282414 Homo sapiens Species 0.000 description 9
- 239000003929 acidic solution Substances 0.000 description 9
- 230000004071 biological effect Effects 0.000 description 9
- 230000003139 buffering effect Effects 0.000 description 9
- 230000001419 dependent effect Effects 0.000 description 9
- 210000002615 epidermis Anatomy 0.000 description 9
- 210000000056 organ Anatomy 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 description 8
- 108010076504 Protein Sorting Signals Proteins 0.000 description 8
- 230000008901 benefit Effects 0.000 description 8
- 210000000845 cartilage Anatomy 0.000 description 8
- 230000000875 corresponding effect Effects 0.000 description 8
- 239000002270 dispersing agent Substances 0.000 description 8
- 239000000835 fiber Substances 0.000 description 8
- 230000014509 gene expression Effects 0.000 description 8
- 230000035772 mutation Effects 0.000 description 8
- 102000040430 polynucleotide Human genes 0.000 description 8
- 108091033319 polynucleotide Proteins 0.000 description 8
- 239000002157 polynucleotide Substances 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 230000017854 proteolysis Effects 0.000 description 8
- 230000002797 proteolythic effect Effects 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 239000005526 vasoconstrictor agent Substances 0.000 description 8
- 239000013598 vector Substances 0.000 description 8
- HYKGUEIYMKVUSR-NPULLEENSA-N 2-(diethylamino)-n-(2,6-dimethylphenyl)acetamide;4-[(1r)-1-hydroxy-2-(methylamino)ethyl]benzene-1,2-diol Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1.CCN(CC)CC(=O)NC1=C(C)C=CC=C1C HYKGUEIYMKVUSR-NPULLEENSA-N 0.000 description 7
- 108010067219 Aggrecans Proteins 0.000 description 7
- 108700028369 Alleles Proteins 0.000 description 7
- 102000029816 Collagenase Human genes 0.000 description 7
- 108060005980 Collagenase Proteins 0.000 description 7
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 7
- 239000007987 MES buffer Substances 0.000 description 7
- 230000001413 cellular effect Effects 0.000 description 7
- 229960002424 collagenase Drugs 0.000 description 7
- 239000012634 fragment Substances 0.000 description 7
- 235000014304 histidine Nutrition 0.000 description 7
- 239000003112 inhibitor Substances 0.000 description 7
- 238000003780 insertion Methods 0.000 description 7
- 230000037431 insertion Effects 0.000 description 7
- 210000003712 lysosome Anatomy 0.000 description 7
- 230000001868 lysosomic effect Effects 0.000 description 7
- 238000003752 polymerase chain reaction Methods 0.000 description 7
- 235000019833 protease Nutrition 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 6
- 102100036601 Aggrecan core protein Human genes 0.000 description 6
- 108090000819 Chondroitin-sulfate-ABC endolyases Proteins 0.000 description 6
- 102000037716 Chondroitin-sulfate-ABC endolyases Human genes 0.000 description 6
- 102000013271 Hemopexin Human genes 0.000 description 6
- 108010026027 Hemopexin Proteins 0.000 description 6
- 102000008055 Heparan Sulfate Proteoglycans Human genes 0.000 description 6
- 108010029485 Protein Isoforms Proteins 0.000 description 6
- 102000001708 Protein Isoforms Human genes 0.000 description 6
- 108090000054 Syndecan-2 Proteins 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 210000000988 bone and bone Anatomy 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- 108010011767 m-calpain Proteins 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 230000035945 sensitivity Effects 0.000 description 6
- 230000000699 topical effect Effects 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 102000003895 Calpain-1 Human genes 0.000 description 5
- 108090000236 Calpain-1 Proteins 0.000 description 5
- 102000003900 Calpain-2 Human genes 0.000 description 5
- 108090000232 Calpain-2 Proteins 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 5
- 102000004157 Hydrolases Human genes 0.000 description 5
- 108090000604 Hydrolases Proteins 0.000 description 5
- 108010067372 Pancreatic elastase Proteins 0.000 description 5
- 102000016387 Pancreatic elastase Human genes 0.000 description 5
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 5
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 5
- 230000035508 accumulation Effects 0.000 description 5
- 238000007792 addition Methods 0.000 description 5
- 230000003444 anaesthetic effect Effects 0.000 description 5
- 229940035674 anesthetics Drugs 0.000 description 5
- 210000002469 basement membrane Anatomy 0.000 description 5
- 230000033228 biological regulation Effects 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
- 230000021164 cell adhesion Effects 0.000 description 5
- 239000003193 general anesthetic agent Substances 0.000 description 5
- 230000007062 hydrolysis Effects 0.000 description 5
- 238000006460 hydrolysis reaction Methods 0.000 description 5
- 230000002427 irreversible effect Effects 0.000 description 5
- 210000002510 keratinocyte Anatomy 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 229910052751 metal Inorganic materials 0.000 description 5
- 239000002184 metal Substances 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 210000002374 sebum Anatomy 0.000 description 5
- 230000002459 sustained effect Effects 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 4
- 229930182837 (R)-adrenaline Natural products 0.000 description 4
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 4
- 229920001287 Chondroitin sulfate Polymers 0.000 description 4
- 101000627854 Homo sapiens Matrix metalloproteinase-26 Proteins 0.000 description 4
- 101100178973 Homo sapiens SPAM1 gene Proteins 0.000 description 4
- 102100021102 Hyaluronidase PH-20 Human genes 0.000 description 4
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 4
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 4
- 102100030417 Matrilysin Human genes 0.000 description 4
- 108090000855 Matrilysin Proteins 0.000 description 4
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 4
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 4
- 102100024128 Matrix metalloproteinase-26 Human genes 0.000 description 4
- 206010027476 Metastases Diseases 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 108010050808 Procollagen Proteins 0.000 description 4
- 108020004511 Recombinant DNA Proteins 0.000 description 4
- 238000012300 Sequence Analysis Methods 0.000 description 4
- PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 description 4
- 108010031318 Vitronectin Proteins 0.000 description 4
- 102100035140 Vitronectin Human genes 0.000 description 4
- 239000000695 adrenergic alpha-agonist Substances 0.000 description 4
- 230000004075 alteration Effects 0.000 description 4
- 229940009098 aspartate Drugs 0.000 description 4
- 238000005844 autocatalytic reaction Methods 0.000 description 4
- 210000004899 c-terminal region Anatomy 0.000 description 4
- 238000006555 catalytic reaction Methods 0.000 description 4
- 150000001768 cations Chemical class 0.000 description 4
- 239000012707 chemical precursor Substances 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 229940059329 chondroitin sulfate Drugs 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 230000007547 defect Effects 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- 210000004177 elastic tissue Anatomy 0.000 description 4
- 229960005139 epinephrine Drugs 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- 230000005714 functional activity Effects 0.000 description 4
- 125000003147 glycosyl group Chemical group 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 4
- 230000000977 initiatory effect Effects 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 229960004194 lidocaine Drugs 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 4
- 230000009401 metastasis Effects 0.000 description 4
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 4
- 238000006386 neutralization reaction Methods 0.000 description 4
- 230000000269 nucleophilic effect Effects 0.000 description 4
- 239000007800 oxidant agent Substances 0.000 description 4
- 230000002035 prolonged effect Effects 0.000 description 4
- 230000000717 retained effect Effects 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 210000002435 tendon Anatomy 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- 230000004572 zinc-binding Effects 0.000 description 4
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 3
- 101710151806 72 kDa type IV collagenase Proteins 0.000 description 3
- 108091022885 ADAM Proteins 0.000 description 3
- 108030006206 Chondroitin-sulfate-ABC exolyases Proteins 0.000 description 3
- 102000011413 Chondroitinases and Chondroitin Lyases Human genes 0.000 description 3
- 108010023736 Chondroitinases and Chondroitin Lyases Proteins 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- 102100027995 Collagenase 3 Human genes 0.000 description 3
- 108050005238 Collagenase 3 Proteins 0.000 description 3
- 241000238424 Crustacea Species 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- 229920000045 Dermatan sulfate Polymers 0.000 description 3
- 102100031780 Endonuclease Human genes 0.000 description 3
- 108010049003 Fibrinogen Proteins 0.000 description 3
- 102000008946 Fibrinogen Human genes 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
- 241000545744 Hirudinea Species 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101001011896 Homo sapiens Matrix metalloproteinase-19 Proteins 0.000 description 3
- 102000003839 Human Proteins Human genes 0.000 description 3
- 108090000144 Human Proteins Proteins 0.000 description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
- 102100027998 Macrophage metalloelastase Human genes 0.000 description 3
- 101710187853 Macrophage metalloelastase Proteins 0.000 description 3
- 102100030218 Matrix metalloproteinase-19 Human genes 0.000 description 3
- 102000004055 Matrix metalloproteinase-19 Human genes 0.000 description 3
- 108090000587 Matrix metalloproteinase-19 Proteins 0.000 description 3
- 102100024130 Matrix metalloproteinase-23 Human genes 0.000 description 3
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 3
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 3
- 108090000973 Myeloblastin Proteins 0.000 description 3
- 102100030411 Neutrophil collagenase Human genes 0.000 description 3
- 101710118230 Neutrophil collagenase Proteins 0.000 description 3
- 108090000526 Papain Proteins 0.000 description 3
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 3
- 102100028848 Stromelysin-2 Human genes 0.000 description 3
- 101710108792 Stromelysin-2 Proteins 0.000 description 3
- 102100028847 Stromelysin-3 Human genes 0.000 description 3
- 108050005271 Stromelysin-3 Proteins 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 101001011890 Xenopus laevis Matrix metalloproteinase-18 Proteins 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 230000009400 cancer invasion Effects 0.000 description 3
- 210000000736 corneocyte Anatomy 0.000 description 3
- AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 description 3
- 229940051593 dermatan sulfate Drugs 0.000 description 3
- 150000002016 disaccharides Chemical group 0.000 description 3
- 230000001747 exhibiting effect Effects 0.000 description 3
- 102000013373 fibrillar collagen Human genes 0.000 description 3
- 108060002894 fibrillar collagen Proteins 0.000 description 3
- 229940012952 fibrinogen Drugs 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 230000013595 glycosylation Effects 0.000 description 3
- 238000006206 glycosylation reaction Methods 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 210000003630 histaminocyte Anatomy 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 238000000099 in vitro assay Methods 0.000 description 3
- 238000005462 in vivo assay Methods 0.000 description 3
- 230000002779 inactivation Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 102000006495 integrins Human genes 0.000 description 3
- 108010044426 integrins Proteins 0.000 description 3
- 210000004692 intercellular junction Anatomy 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 239000008176 lyophilized powder Substances 0.000 description 3
- 229920002521 macromolecule Polymers 0.000 description 3
- 229930182817 methionine Natural products 0.000 description 3
- 238000001823 molecular biology technique Methods 0.000 description 3
- 229940055729 papain Drugs 0.000 description 3
- 235000019834 papain Nutrition 0.000 description 3
- 244000045947 parasite Species 0.000 description 3
- 230000006320 pegylation Effects 0.000 description 3
- 230000004962 physiological condition Effects 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 125000003396 thiol group Chemical group [H]S* 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 230000029663 wound healing Effects 0.000 description 3
- GEFQWZLICWMTKF-CDUCUWFYSA-N (-)-alpha-Methylnoradrenaline Chemical compound C[C@H](N)[C@H](O)C1=CC=C(O)C(O)=C1 GEFQWZLICWMTKF-CDUCUWFYSA-N 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 2
- VKUYLANQOAKALN-UHFFFAOYSA-N 2-[benzyl-(4-methoxyphenyl)sulfonylamino]-n-hydroxy-4-methylpentanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(CC(C)C)C(=O)NO)CC1=CC=CC=C1 VKUYLANQOAKALN-UHFFFAOYSA-N 0.000 description 2
- IVLXQGJVBGMLRR-UHFFFAOYSA-N 2-aminoacetic acid;hydron;chloride Chemical compound Cl.NCC(O)=O IVLXQGJVBGMLRR-UHFFFAOYSA-N 0.000 description 2
- LKDMKWNDBAVNQZ-UHFFFAOYSA-N 4-[[1-[[1-[2-[[1-(4-nitroanilino)-1-oxo-3-phenylpropan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-oxobutanoic acid Chemical compound OC(=O)CCC(=O)NC(C)C(=O)NC(C)C(=O)N1CCCC1C(=O)NC(C(=O)NC=1C=CC(=CC=1)[N+]([O-])=O)CC1=CC=CC=C1 LKDMKWNDBAVNQZ-UHFFFAOYSA-N 0.000 description 2
- 102100027400 A disintegrin and metalloproteinase with thrombospondin motifs 4 Human genes 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-M Aminoacetate Chemical compound NCC([O-])=O DHMQDGOQFOQNFH-UHFFFAOYSA-M 0.000 description 2
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 2
- 208000035404 Autolysis Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 101000898643 Candida albicans Vacuolar aspartic protease Proteins 0.000 description 2
- 102000005367 Carboxypeptidases Human genes 0.000 description 2
- 108010006303 Carboxypeptidases Proteins 0.000 description 2
- 102000004173 Cathepsin G Human genes 0.000 description 2
- 108090000617 Cathepsin G Proteins 0.000 description 2
- 102000000844 Cell Surface Receptors Human genes 0.000 description 2
- 108010001857 Cell Surface Receptors Proteins 0.000 description 2
- 206010057248 Cell death Diseases 0.000 description 2
- 102000018963 Chondroitin Lyases Human genes 0.000 description 2
- 108010026719 Chondroitin Lyases Proteins 0.000 description 2
- 102100024539 Chymase Human genes 0.000 description 2
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
- 102000004237 Decorin Human genes 0.000 description 2
- 108090000738 Decorin Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- 102000013382 Gelatinases Human genes 0.000 description 2
- 108010026132 Gelatinases Proteins 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 101000585728 Homo sapiens Protein O-GlcNAcase Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 150000008575 L-amino acids Chemical group 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- 102000004317 Lyases Human genes 0.000 description 2
- 108090000856 Lyases Proteins 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 108010076557 Matrix Metalloproteinase 14 Proteins 0.000 description 2
- 102100030216 Matrix metalloproteinase-14 Human genes 0.000 description 2
- 108090000560 Matrix metalloproteinase-15 Proteins 0.000 description 2
- 108090000561 Matrix metalloproteinase-16 Proteins 0.000 description 2
- 108090000585 Matrix metalloproteinase-17 Proteins 0.000 description 2
- 101710082411 Matrix metalloproteinase-21 Proteins 0.000 description 2
- 102100024129 Matrix metalloproteinase-24 Human genes 0.000 description 2
- 108050005214 Matrix metalloproteinase-24 Proteins 0.000 description 2
- 102100026799 Matrix metalloproteinase-28 Human genes 0.000 description 2
- 102100034681 Myeloblastin Human genes 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 102100033174 Neutrophil elastase Human genes 0.000 description 2
- 102000000641 Non-Fibrillar Collagens Human genes 0.000 description 2
- 108010002466 Non-Fibrillar Collagens Proteins 0.000 description 2
- 241000605114 Pedobacter heparinus Species 0.000 description 2
- 108091093037 Peptide nucleic acid Proteins 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 101150055528 SPAM1 gene Proteins 0.000 description 2
- 101000898773 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Saccharopepsin Proteins 0.000 description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 102100030416 Stromelysin-1 Human genes 0.000 description 2
- 101710108790 Stromelysin-1 Proteins 0.000 description 2
- 101710172711 Structural protein Proteins 0.000 description 2
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 2
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- 108060005989 Tryptase Proteins 0.000 description 2
- 102000001400 Tryptase Human genes 0.000 description 2
- 206010064390 Tumour invasion Diseases 0.000 description 2
- 241000269370 Xenopus <genus> Species 0.000 description 2
- 230000001594 aberrant effect Effects 0.000 description 2
- 239000000464 adrenergic agent Substances 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000031018 biological processes and functions Effects 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- 230000004097 bone metabolism Effects 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 150000007942 carboxylates Chemical group 0.000 description 2
- 230000008414 cartilage metabolism Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 229950008484 corbadrine Drugs 0.000 description 2
- 210000004087 cornea Anatomy 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000007857 degradation product Substances 0.000 description 2
- 230000003413 degradative effect Effects 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- 230000005595 deprotonation Effects 0.000 description 2
- 238000010537 deprotonation reaction Methods 0.000 description 2
- 230000001687 destabilization Effects 0.000 description 2
- VILAVOFMIJHSJA-UHFFFAOYSA-N dicarbon monoxide Chemical compound [C]=C=O VILAVOFMIJHSJA-UHFFFAOYSA-N 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 230000013020 embryo development Effects 0.000 description 2
- 230000023117 embryonic morphogenesis Effects 0.000 description 2
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 2
- 210000001163 endosome Anatomy 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 2
- 102000034240 fibrous proteins Human genes 0.000 description 2
- 108091005899 fibrous proteins Proteins 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 210000003780 hair follicle Anatomy 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 102000046319 human OGA Human genes 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000004968 inflammatory condition Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 210000003041 ligament Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- 108090000440 matrix metalloproteinase 25 Proteins 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 229960002748 norepinephrine Drugs 0.000 description 2
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 2
- 150000002894 organic compounds Chemical class 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 239000002831 pharmacologic agent Substances 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 150000004804 polysaccharides Polymers 0.000 description 2
- 230000004481 post-translational protein modification Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 108010028075 procathepsin L Proteins 0.000 description 2
- 210000001236 prokaryotic cell Anatomy 0.000 description 2
- 230000005588 protonation Effects 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000010188 recombinant method Methods 0.000 description 2
- 238000009877 rendering Methods 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000028043 self proteolysis Effects 0.000 description 2
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 210000000434 stratum corneum Anatomy 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 150000003573 thiols Chemical class 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- 230000007838 tissue remodeling Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 230000037314 wound repair Effects 0.000 description 2
- OIXLLKLZKCBCPS-RZVRUWJTSA-N (2s)-2-azanyl-5-[bis(azanyl)methylideneamino]pentanoic acid Chemical compound OC(=O)[C@@H](N)CCCNC(N)=N.OC(=O)[C@@H](N)CCCNC(N)=N OIXLLKLZKCBCPS-RZVRUWJTSA-N 0.000 description 1
- CVYPRDPBCXSVBN-WDZFZDKYSA-N (5z)-5-[[5-[(4-chlorophenyl)methylsulfanyl]-1-methyl-3-(trifluoromethyl)pyrazol-4-yl]methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound C=1C=C(Cl)C=CC=1CSC=1N(C)N=C(C(F)(F)F)C=1\C=C1/SC(=S)NC1=O CVYPRDPBCXSVBN-WDZFZDKYSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 1
- DJQYYYCQOZMCRC-UHFFFAOYSA-N 2-aminopropane-1,3-dithiol Chemical compound SCC(N)CS DJQYYYCQOZMCRC-UHFFFAOYSA-N 0.000 description 1
- 102100027398 A disintegrin and metalloproteinase with thrombospondin motifs 1 Human genes 0.000 description 1
- 102100032310 A disintegrin and metalloproteinase with thrombospondin motifs 14 Human genes 0.000 description 1
- 101710100366 A disintegrin and metalloproteinase with thrombospondin motifs 2 Proteins 0.000 description 1
- 102100027401 A disintegrin and metalloproteinase with thrombospondin motifs 3 Human genes 0.000 description 1
- 102100032638 A disintegrin and metalloproteinase with thrombospondin motifs 5 Human genes 0.000 description 1
- 108091005660 ADAMTS1 Proteins 0.000 description 1
- 108091005664 ADAMTS4 Proteins 0.000 description 1
- 108091005663 ADAMTS5 Proteins 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- FKBFDTRILNZGAI-IMJSIDKUSA-N Asp-Cys Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CS)C(O)=O FKBFDTRILNZGAI-IMJSIDKUSA-N 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 102000030431 Asparaginyl endopeptidase Human genes 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 102100036597 Basement membrane-specific heparan sulfate proteoglycan core protein Human genes 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 102100035687 Bile salt-activated lipase Human genes 0.000 description 1
- 101710130200 Bile salt-activated lipase Proteins 0.000 description 1
- 102100029398 Calpain small subunit 1 Human genes 0.000 description 1
- 101710131373 Calpain small subunit 1 Proteins 0.000 description 1
- 102100035037 Calpastatin Human genes 0.000 description 1
- 101000898783 Candida tropicalis Candidapepsin Proteins 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 102100026657 Cathepsin Z Human genes 0.000 description 1
- 108010061117 Cathepsin Z Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 208000018380 Chemical injury Diseases 0.000 description 1
- 229920002567 Chondroitin Polymers 0.000 description 1
- 101710106625 Chondroitinase-AC Proteins 0.000 description 1
- 108090000227 Chymases Proteins 0.000 description 1
- 101710138848 Chymotrypsin-like elastase family member 1 Proteins 0.000 description 1
- 102100023335 Chymotrypsin-like elastase family member 2A Human genes 0.000 description 1
- 101710149623 Chymotrypsin-like elastase family member 2A Proteins 0.000 description 1
- 102100023338 Chymotrypsin-like elastase family member 2B Human genes 0.000 description 1
- 102100023336 Chymotrypsin-like elastase family member 3B Human genes 0.000 description 1
- 108020004638 Circular DNA Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 102000012432 Collagen Type V Human genes 0.000 description 1
- 108010022514 Collagen Type V Proteins 0.000 description 1
- 102000000989 Complement System Proteins Human genes 0.000 description 1
- 108010069112 Complement System Proteins Proteins 0.000 description 1
- 102000003706 Complement factor D Human genes 0.000 description 1
- 108090000059 Complement factor D Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 101000898784 Cryphonectria parasitica Endothiapepsin Proteins 0.000 description 1
- LVNMAAGSAUGNIC-BQBZGAKWSA-N Cys-His Chemical compound SC[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CNC=N1 LVNMAAGSAUGNIC-BQBZGAKWSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000010831 Cytoskeletal Proteins Human genes 0.000 description 1
- 108010037414 Cytoskeletal Proteins Proteins 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 101800001224 Disintegrin Proteins 0.000 description 1
- 101710099240 Elastase-1 Proteins 0.000 description 1
- 102000005593 Endopeptidases Human genes 0.000 description 1
- 108010059378 Endopeptidases Proteins 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 102000018389 Exopeptidases Human genes 0.000 description 1
- 108010091443 Exopeptidases Proteins 0.000 description 1
- 108010074860 Factor Xa Proteins 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 101710163305 Fibril protein Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 241000589565 Flavobacterium Species 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 241000855538 Gallacea scleroderma Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 102100031416 Gastric triacylglycerol lipase Human genes 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 1
- 108010053070 Glutathione Disulfide Proteins 0.000 description 1
- 241000282575 Gorilla Species 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 102000001398 Granzyme Human genes 0.000 description 1
- 108060005986 Granzyme Proteins 0.000 description 1
- 101000572796 Hepatitis E virus genotype 1 (isolate Human/China/HeBei/1987) RNA-directed RNA polymerase Proteins 0.000 description 1
- 101000798295 Homo sapiens A disintegrin and metalloproteinase with thrombospondin motifs 14 Proteins 0.000 description 1
- 101000936403 Homo sapiens A disintegrin and metalloproteinase with thrombospondin motifs 2 Proteins 0.000 description 1
- 101000936395 Homo sapiens A disintegrin and metalloproteinase with thrombospondin motifs 3 Proteins 0.000 description 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 1
- 101000761509 Homo sapiens Cathepsin K Proteins 0.000 description 1
- 101000910979 Homo sapiens Cathepsin Z Proteins 0.000 description 1
- 101000907961 Homo sapiens Chymotrypsin-like elastase family member 2B Proteins 0.000 description 1
- 101000962530 Homo sapiens Hyaluronidase-1 Proteins 0.000 description 1
- 101000962526 Homo sapiens Hyaluronidase-2 Proteins 0.000 description 1
- 101001041128 Homo sapiens Hyaluronidase-3 Proteins 0.000 description 1
- 101001041120 Homo sapiens Hyaluronidase-4 Proteins 0.000 description 1
- 101000627861 Homo sapiens Matrix metalloproteinase-28 Proteins 0.000 description 1
- 101000983583 Homo sapiens Procathepsin L Proteins 0.000 description 1
- 102100039283 Hyaluronidase-1 Human genes 0.000 description 1
- 102100039285 Hyaluronidase-2 Human genes 0.000 description 1
- 102100021081 Hyaluronidase-4 Human genes 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 206010023330 Keloid scar Diseases 0.000 description 1
- 229920000288 Keratan sulfate Polymers 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 108010028275 Leukocyte Elastase Proteins 0.000 description 1
- 206010049287 Lipodystrophy acquired Diseases 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102100026001 Lysosomal acid lipase/cholesteryl ester hydrolase Human genes 0.000 description 1
- 108091007144 MMP23A Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000004043 Matrix metalloproteinase-15 Human genes 0.000 description 1
- 102100030201 Matrix metalloproteinase-15 Human genes 0.000 description 1
- 102000004044 Matrix metalloproteinase-16 Human genes 0.000 description 1
- 102100030200 Matrix metalloproteinase-16 Human genes 0.000 description 1
- 102000004054 Matrix metalloproteinase-17 Human genes 0.000 description 1
- 102100030219 Matrix metalloproteinase-17 Human genes 0.000 description 1
- 108090000609 Matrix metalloproteinase-20 Proteins 0.000 description 1
- 102000004159 Matrix metalloproteinase-20 Human genes 0.000 description 1
- 108050006284 Matrix metalloproteinase-23 Proteins 0.000 description 1
- 102100024131 Matrix metalloproteinase-25 Human genes 0.000 description 1
- 102100024132 Matrix metalloproteinase-27 Human genes 0.000 description 1
- 108050005201 Matrix metalloproteinase-27 Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 108091092724 Noncoding DNA Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 241000157908 Paenarthrobacter aurescens Species 0.000 description 1
- 101000909992 Papio hamadryas Chymase Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- WGVWLKXZBUVUAM-UHFFFAOYSA-N Pentanochlor Chemical compound CCCC(C)C(=O)NC1=CC=C(C)C(Cl)=C1 WGVWLKXZBUVUAM-UHFFFAOYSA-N 0.000 description 1
- 108010064785 Phospholipases Proteins 0.000 description 1
- 102000015439 Phospholipases Human genes 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- WVOXLKUUVCCCSU-ZPFDUUQYSA-N Pro-Glu-Ile Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O WVOXLKUUVCCCSU-ZPFDUUQYSA-N 0.000 description 1
- 102100038931 Proenkephalin-A Human genes 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 241000588767 Proteus vulgaris Species 0.000 description 1
- 101000910471 Proteus vulgaris Chondroitin sulfate ABC endolyase Proteins 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 241000485664 Protortonia cacti Species 0.000 description 1
- 230000004570 RNA-binding Effects 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000700162 Rattus sp. Species 0.000 description 1
- 101000933133 Rhizopus niveus Rhizopuspepsin-1 Proteins 0.000 description 1
- 101000910082 Rhizopus niveus Rhizopuspepsin-2 Proteins 0.000 description 1
- 101000910079 Rhizopus niveus Rhizopuspepsin-3 Proteins 0.000 description 1
- 101000910086 Rhizopus niveus Rhizopuspepsin-4 Proteins 0.000 description 1
- 101000910088 Rhizopus niveus Rhizopuspepsin-5 Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000282849 Ruminantia Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010055297 Sterol Esterase Proteins 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 229940127321 Structural Macromolecules Drugs 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 102000019361 Syndecan Human genes 0.000 description 1
- 108050006774 Syndecan Proteins 0.000 description 1
- 108700005078 Synthetic Genes Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 102000035100 Threonine proteases Human genes 0.000 description 1
- 108091005501 Threonine proteases Proteins 0.000 description 1
- 102000002938 Thrombospondin Human genes 0.000 description 1
- 108060008245 Thrombospondin Proteins 0.000 description 1
- 102100033663 Transforming growth factor beta receptor type 3 Human genes 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 241000703751 Victivallis vadensis Species 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 102000036861 Zinc-dependent endopeptidases Human genes 0.000 description 1
- 108091006982 Zinc-dependent endopeptidases Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- RXSUFCOOZSGWSW-UHFFFAOYSA-M acetyloxy-(4-aminophenyl)mercury Chemical compound CC(=O)O[Hg]C1=CC=C(N)C=C1 RXSUFCOOZSGWSW-UHFFFAOYSA-M 0.000 description 1
- 238000007171 acid catalysis Methods 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 210000004507 artificial chromosome Anatomy 0.000 description 1
- 210000001106 artificial yeast chromosome Anatomy 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 108010055066 asparaginylendopeptidase Proteins 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-L aspartate group Chemical group N[C@@H](CC(=O)[O-])C(=O)[O-] CKLJMWTZIZZHCS-REOHCLBHSA-L 0.000 description 1
- 150000001510 aspartic acids Chemical class 0.000 description 1
- 108010041102 azocasein Proteins 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 238000005815 base catalysis Methods 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 108010079292 betaglycan Proteins 0.000 description 1
- 239000012867 bioactive agent Substances 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 230000003185 calcium uptake Effects 0.000 description 1
- 108010044208 calpastatin Proteins 0.000 description 1
- ZXJCOYBPXOBJMU-HSQGJUDPSA-N calpastatin peptide Ac 184-210 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCSC)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(O)=O)NC(C)=O)[C@@H](C)O)C1=CC=C(O)C=C1 ZXJCOYBPXOBJMU-HSQGJUDPSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 108020001778 catalytic domains Proteins 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 238000004182 chemical digestion Methods 0.000 description 1
- 239000013626 chemical specie Substances 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 208000035196 congenital hypomyelinating 2 neuropathy Diseases 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 210000003298 dental enamel Anatomy 0.000 description 1
- 210000004268 dentin Anatomy 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 150000002019 disulfides Chemical class 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 229940066758 endopeptidases Drugs 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 230000009088 enzymatic function Effects 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000028023 exocytosis Effects 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 102000013370 fibrillin Human genes 0.000 description 1
- 108060002895 fibrillin Proteins 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 108010020275 fibrin receptor Proteins 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 108010091264 gastric triacylglycerol lipase Proteins 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-L glutamate group Chemical group N[C@@H](CCC(=O)[O-])C(=O)[O-] WHUUTDBJXJRKMK-VKHMYHEASA-L 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 108010057863 heparin receptor Proteins 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000126 in silico method Methods 0.000 description 1
- 238000007850 in situ PCR Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000012212 insulator Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000035992 intercellular communication Effects 0.000 description 1
- 230000008611 intercellular interaction Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- KXCLCNHUUKTANI-RBIYJLQWSA-N keratan Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@H](COS(O)(=O)=O)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H]([C@@H](COS(O)(=O)=O)O[C@@H](O)[C@@H]3O)O)[C@H](NC(C)=O)[C@H]2O)COS(O)(=O)=O)O[C@H](COS(O)(=O)=O)[C@@H]1O KXCLCNHUUKTANI-RBIYJLQWSA-N 0.000 description 1
- 108010057670 laminin 1 Proteins 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 238000007854 ligation-mediated PCR Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 208000006132 lipodystrophy Diseases 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000007443 liposuction Methods 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 238000007403 mPCR Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-L malate(2-) Chemical compound [O-]C(=O)C(O)CC([O-])=O BJEPYKJPYRNKOW-UHFFFAOYSA-L 0.000 description 1
- 210000000723 mammalian artificial chromosome Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000003716 mesoderm Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000001724 microfibril Anatomy 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000001089 mineralizing effect Effects 0.000 description 1
- 230000004001 molecular interaction Effects 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- UPSFMJHZUCSEHU-JYGUBCOQSA-N n-[(2s,3r,4r,5s,6r)-2-[(2r,3s,4r,5r,6s)-5-acetamido-4-hydroxy-2-(hydroxymethyl)-6-(4-methyl-2-oxochromen-7-yl)oxyoxan-3-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide Chemical compound CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](O)[C@@H](NC(C)=O)[C@H](OC=2C=C3OC(=O)C=C(C)C3=CC=2)O[C@@H]1CO UPSFMJHZUCSEHU-JYGUBCOQSA-N 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 230000014511 neuron projection development Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 235000020925 non fasting Nutrition 0.000 description 1
- ZVEZMVFBMOOHAT-UHFFFAOYSA-N nonane-1-thiol Chemical compound CCCCCCCCCS ZVEZMVFBMOOHAT-UHFFFAOYSA-N 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- YPZRWBKMTBYPTK-UHFFFAOYSA-N oxidized gamma-L-glutamyl-L-cysteinylglycine Natural products OC(=O)C(N)CCC(=O)NC(C(=O)NCC(O)=O)CSSCC(C(=O)NCC(O)=O)NC(=O)CCC(N)C(O)=O YPZRWBKMTBYPTK-UHFFFAOYSA-N 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 108090000155 pancreatic elastase II Proteins 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 108010049224 perlecan Proteins 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 239000012985 polymerization agent Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 108010028069 procathepsin B Proteins 0.000 description 1
- 108010041071 proenkephalin Proteins 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 230000007065 protein hydrolysis Effects 0.000 description 1
- 229940121649 protein inhibitor Drugs 0.000 description 1
- 239000012268 protein inhibitor Substances 0.000 description 1
- 230000004844 protein turnover Effects 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 229940007042 proteus vulgaris Drugs 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 102000037983 regulatory factors Human genes 0.000 description 1
- 108091008025 regulatory factors Proteins 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000004739 secretory vesicle Anatomy 0.000 description 1
- 238000001338 self-assembly Methods 0.000 description 1
- 102000015340 serglycin Human genes 0.000 description 1
- 108010050065 serglycin Proteins 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 235000021309 simple sugar Nutrition 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000000438 stratum basale Anatomy 0.000 description 1
- 210000000498 stratum granulosum Anatomy 0.000 description 1
- 210000000439 stratum lucidum Anatomy 0.000 description 1
- 210000000437 stratum spinosum Anatomy 0.000 description 1
- 230000007847 structural defect Effects 0.000 description 1
- 239000008362 succinate buffer Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 150000007970 thio esters Chemical class 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 210000000515 tooth Anatomy 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 108010087967 type I signal peptidase Proteins 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 229910052720 vanadium Inorganic materials 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 210000004127 vitreous body Anatomy 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 230000034365 zymogen activation Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4813—Exopeptidases (3.4.11. to 3.4.19)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4873—Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/488—Aspartic endopeptidases (3.4.23), e.g. pepsin, chymosin, renin, cathepsin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6472—Cysteine endopeptidases (3.4.22)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6489—Metalloendopeptidases (3.4.24)
- C12N9/6491—Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/22—Cysteine endopeptidases (3.4.22)
- C12Y304/22015—Cathepsin L (3.4.22.15)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24007—Interstitial collagenase (3.4.24.7), i.e. matrix metalloprotease 1 or MMP1
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Marine Sciences & Fisheries (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6866708P | 2008-03-06 | 2008-03-06 | |
| US61/068,667 | 2008-03-06 | ||
| US12772508P | 2008-05-14 | 2008-05-14 | |
| US61/127,725 | 2008-05-14 | ||
| PCT/US2009/001486 WO2009111083A2 (en) | 2008-03-06 | 2009-03-06 | In vivo temporal control of activ at able matrix- degrading enzymes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2718549A1 CA2718549A1 (en) | 2009-09-11 |
| CA2718549C true CA2718549C (en) | 2016-08-09 |
Family
ID=41017153
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2718549A Expired - Fee Related CA2718549C (en) | 2008-03-06 | 2009-03-06 | In vivo temporal control of activatable matrix-degrading enzymes |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US9833498B2 (https=) |
| EP (1) | EP2274004B1 (https=) |
| JP (2) | JP5709531B2 (https=) |
| KR (3) | KR20100135779A (https=) |
| AR (1) | AR076627A1 (https=) |
| AU (1) | AU2009220094B2 (https=) |
| BR (1) | BRPI0909622A2 (https=) |
| CA (1) | CA2718549C (https=) |
| CL (2) | CL2009000541A1 (https=) |
| CO (1) | CO6331294A2 (https=) |
| ES (1) | ES2586765T3 (https=) |
| IL (1) | IL207293A (https=) |
| MX (1) | MX2010009806A (https=) |
| TW (1) | TWI395593B (https=) |
| WO (1) | WO2009111083A2 (https=) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2508948A1 (en) | 2002-12-16 | 2004-07-15 | Halozyme, Inc. | Human chondroitinase glycoprotein (chasegp), process for preparing the same, and pharmaceutical compositions comprising thereof |
| US20090123367A1 (en) * | 2003-03-05 | 2009-05-14 | Delfmems | Soluble Glycosaminoglycanases and Methods of Preparing and Using Soluble Glycosaminoglycanases |
| NZ542873A (en) | 2003-03-05 | 2008-07-31 | Halozyme Inc | Soluble, neutral-active hyaluronidase activity glycoprotein (sHASEGP) that is produced with high yield in a mammalian expression system by introducing nucleic acids that lack a narrow region encoding amino acids in the carboxy terminus of the human PH20 cDNA |
| US7871607B2 (en) * | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| TWI395593B (zh) | 2008-03-06 | 2013-05-11 | Halozyme Inc | 可活化的基質降解酵素之活體內暫時性控制 |
| TWI489994B (zh) | 2008-03-17 | 2015-07-01 | Baxter Healthcare Sa | 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法 |
| KR20130116386A (ko) * | 2008-04-14 | 2013-10-23 | 할로자임, 아이엔씨 | 히알루로난 관련 질환 및 상태 치료용 변형된 히알루로니다제 및 그 용도 |
| TWI394580B (zh) * | 2008-04-28 | 2013-05-01 | Halozyme Inc | 超快起作用胰島素組成物 |
| EA022752B1 (ru) * | 2008-12-09 | 2016-02-29 | Галозим, Инк. | Длинные растворимые полипептиды рн20 и их использование |
| EP2403523A1 (en) * | 2009-03-06 | 2012-01-11 | Halozyme, Inc. | Temperature sensitive mutants of matrix metalloprotease 1 und uses thereof |
| NZ604050A (en) | 2010-06-11 | 2014-10-31 | Dvo Inc | Nutrient recovery systems and methods |
| WO2012012300A2 (en) | 2010-07-20 | 2012-01-26 | Halozyme, Inc. | Adverse side-effects associated with administration of an anti-hyaluronan agent and methods for ameliorating or preventing the side-effects |
| MX349622B (es) | 2010-09-08 | 2017-08-07 | Halozyme Inc | Metodos para evaluar e identificar o evolucionar proteinas terapeuticas condicionalmente activas. |
| WO2012048291A2 (en) * | 2010-10-08 | 2012-04-12 | Proteapex Therapeutics Llc | Compositions and methods for inhibition of mmp:mmp-substrate interactions |
| US9414930B2 (en) | 2010-10-26 | 2016-08-16 | Kyphon SÀRL | Activatable devices containing a chemonucleolysis agent |
| US8404268B2 (en) | 2010-10-26 | 2013-03-26 | Kyphon Sarl | Locally targeted anti-fibrotic agents and methods of use |
| US8740982B2 (en) | 2010-10-26 | 2014-06-03 | Kyphon Sarl | Devices containing a chemonucleolysis agent and methods for treating an intervertebral disc or spinal arachnoiditis |
| WO2012155212A1 (en) * | 2011-05-18 | 2012-11-22 | David Chin | Method of treating excessive collagen formation |
| JP5860651B2 (ja) * | 2011-09-30 | 2016-02-16 | オリンパス株式会社 | ホタル由来ルシフェラーゼ |
| FR2984130A1 (fr) * | 2011-12-14 | 2013-06-21 | Oreal | Utilisation de la proteine mmp-12 dans la prevention et/ou le traitement des peaux vieillies ou senescentes. |
| FR2984127A1 (fr) * | 2011-12-14 | 2013-06-21 | Oreal | Utilisation de la proteine mmp-12 dans la prevention et/ou le traitement des peaux grasses et/ou a tendance grasse. |
| FR2984128A1 (fr) * | 2011-12-14 | 2013-06-21 | Oreal | Utilisation de la proteine mmp-12 dans la prevention et/ou le traitement des peaux sensibles. |
| FR2984129B1 (fr) * | 2011-12-14 | 2014-01-10 | Oreal | Utilisation de la proteine mmp-12 dans la prevention et/ou le traitement des etats pelliculaires du cuir chevelu |
| CN108686203A (zh) | 2012-04-04 | 2018-10-23 | 哈洛齐梅公司 | 使用抗透明质酸剂和肿瘤靶向紫杉烷的组合疗法 |
| EP2852403B1 (en) | 2012-04-30 | 2018-03-07 | Elastomics AB | Methods for modification of tissues |
| WO2014107745A1 (en) * | 2013-01-07 | 2014-07-10 | Halozyme, Inc. | Metal sensitive mutants of matrix metalloproteases and uses thereof |
| WO2014172526A1 (en) * | 2013-04-18 | 2014-10-23 | Drexel University | Novel methods of use of biomimetic proteoglycans |
| CA2920835A1 (en) | 2013-08-20 | 2015-02-26 | Anutra Medical, Inc. | Syringe fill system and method |
| EP3052095A4 (en) * | 2013-10-03 | 2017-07-05 | Imprimis Pharmaceuticals Inc. | Epinephrine-based ophthalmic compositions for intraocular administration and methods for fabricating thereof |
| FI127924B (en) * | 2014-02-27 | 2019-05-31 | Oy Medix Biochemica Ab | METHOD OF MEASURING MMP-8 ACTIVATION |
| USD763433S1 (en) | 2014-06-06 | 2016-08-09 | Anutra Medical, Inc. | Delivery system cassette |
| USD750768S1 (en) | 2014-06-06 | 2016-03-01 | Anutra Medical, Inc. | Fluid administration syringe |
| USD774182S1 (en) | 2014-06-06 | 2016-12-13 | Anutra Medical, Inc. | Anesthetic delivery device |
| LT3388075T (lt) | 2015-03-27 | 2023-11-10 | Immatics Biotechnologies Gmbh | Nauji peptidai ir peptidų deriniai, skirti naudoti imunoterapijai prieš įvairius navikus (seq id 25 - mrax5-003) |
| GB201505305D0 (en) | 2015-03-27 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel Peptides and combination of peptides for use in immunotherapy against various tumors |
| US10493247B2 (en) | 2016-03-15 | 2019-12-03 | Medtronic Holding Company Sàrl | Devices for delivering a chemical denervation agent and methods of use |
| EP3503873A4 (en) | 2016-08-25 | 2020-04-15 | Harrow IP, LLC | EPINEPHRINE-BASED OPHTHALMIC COMPOSITIONS FOR INTRAOCULAR ADMINISTRATION AND METHOD FOR THE PRODUCTION THEREOF |
| US10758559B1 (en) | 2017-09-01 | 2020-09-01 | University Of Wyoming | Targeting cathepsin K to facilitate wound healing |
| US11766467B2 (en) | 2017-09-01 | 2023-09-26 | University Of Wyoming | Methods of treating wounds using cathepsin K inhibitors |
| WO2019182745A1 (en) | 2018-03-19 | 2019-09-26 | Bryn Pharma, LLC | Epinephrine spray formulations |
| AU2019271132B2 (en) * | 2018-05-15 | 2026-02-05 | Translate Bio, Inc. | Subcutaneous delivery of messenger RNA |
| EP3931330A4 (en) | 2019-02-25 | 2023-03-15 | Ginkgo Bioworks, Inc. | BIOSYNTHESIS OF CANNABINOIDS AND CANNABINOID PRECURSORS |
| JP7316647B2 (ja) * | 2019-07-16 | 2023-07-28 | 日本メナード化粧品株式会社 | カテプシンｖ活性促進剤及びｇａｔａ－３産生抑制剤 |
| MX2022003768A (es) * | 2019-10-03 | 2022-08-19 | Vitruvia Holdings Inc | Metodo de restauracion del tejido conectivo. |
| US20230190881A1 (en) | 2020-02-17 | 2023-06-22 | Biotest Ag | Subcutaneous administration of factor viii |
| CN115702242A (zh) * | 2020-04-20 | 2023-02-14 | 医药控股公司 | 一种改性的细菌透明质酸酶多肽、生产方法、药物组合物及其用途 |
| US11370973B2 (en) | 2020-07-10 | 2022-06-28 | Saudi Arabian Oil Company | Processes and systems for producing one or more of benzene, toluene, or mixed xylenes |
| KR102486046B1 (ko) | 2020-12-14 | 2023-01-11 | 주식회사 뉴온바이오 | 근육질환, 비만 또는 당뇨병 치료, 또는 예방용 조성물 |
| TW202308689A (zh) * | 2021-04-21 | 2023-03-01 | 美商健生生物科技公司 | 高濃度的雙特異性抗體調配物 |
| GB2607584B (en) * | 2021-06-03 | 2024-07-17 | Stichting Medische Kliniek Velsen | Composition and method of treatment |
| CN115786302A (zh) * | 2022-12-28 | 2023-03-14 | 无锡蔚蓝生物科技有限公司 | 脂肪酶突变体及其在白酒黄水处理中的应用 |
Family Cites Families (153)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3539794A (en) | 1967-09-12 | 1970-11-10 | American Cyanamid Co | Self-contained chemiluminescent lighting device |
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3630200A (en) | 1969-06-09 | 1971-12-28 | Alza Corp | Ocular insert |
| US3710795A (en) | 1970-09-29 | 1973-01-16 | Alza Corp | Drug-delivery device with stretched, rate-controlling membrane |
| US3847770A (en) | 1972-04-10 | 1974-11-12 | Continental Can Co | Photopolymerizable compositions prepared from beta hydroxy esters and polyitaconates |
| US4044126A (en) | 1972-04-20 | 1977-08-23 | Allen & Hanburys Limited | Steroidal aerosol compositions and process for the preparation thereof |
| GB1429184A (en) | 1972-04-20 | 1976-03-24 | Allen & Hanburys Ltd | Physically anti-inflammatory steroids for use in aerosols |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4002531A (en) | 1976-01-22 | 1977-01-11 | Pierce Chemical Company | Modifying enzymes with polyethylene glycol and product produced thereby |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| LU76148A1 (https=) | 1976-11-08 | 1978-07-10 | ||
| SU787035A1 (ru) | 1978-01-11 | 1980-12-15 | Всесоюзный научно-исследовательский и испытательный институт медицинской техники | Устройство дл введени лекарственных препаратов |
| US4202314A (en) | 1978-11-20 | 1980-05-13 | Busygin Valery P | Device for injection of medicinal preparations |
| JPS57128634A (en) | 1981-02-03 | 1982-08-10 | Eisai Co Ltd | Elastase-containing compound increasing absorption |
| EP0072057B1 (en) | 1981-08-10 | 1988-02-10 | Duphar International Research B.V | Automatic injection syringe |
| US4645668A (en) * | 1983-08-04 | 1987-02-24 | Biospecifics, Nv | Method for the prevention and treatment of scars with enzymes |
| US4952496A (en) | 1984-03-30 | 1990-08-28 | Associated Universities, Inc. | Cloning and expression of the gene for bacteriophage T7 RNA polymerase |
| US4769027A (en) | 1984-08-15 | 1988-09-06 | Burroughs Wellcome Co. | Delivery system |
| US4687610A (en) | 1986-04-30 | 1987-08-18 | E. I. Du Pont De Neumours And Company | Low crystallinity polyester yarn produced at ultra high spinning speeds |
| SE457417B (sv) | 1987-04-14 | 1988-12-27 | Astra Meditec Ab | Automatisk tvaakammarspruta, foerfarande foer blandning och injicering med sprutan samt ampull foer tvaakammarspruta |
| GB2205643B (en) | 1987-05-08 | 1991-03-13 | Farmos Group Limited | Type iii collagen degradation assay |
| US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
| US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| US5122614A (en) | 1989-04-19 | 1992-06-16 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
| US5324844A (en) | 1989-04-19 | 1994-06-28 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
| DE3921528A1 (de) | 1989-06-30 | 1991-01-10 | Draegerwerk Ag | Messzelle fuer den elektrochemischen gasnachweis |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5051449A (en) | 1991-02-27 | 1991-09-24 | Kligman Albert M | Treatment of cellulite with retinoids |
| GB9105893D0 (en) | 1991-03-20 | 1991-05-08 | Orion Yhtymae Oy | Bone resorption assay based on a peptide liberated during collagen degradation |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| US5171081A (en) | 1992-05-29 | 1992-12-15 | Pita Joe W | Chemiluminescent reactive vessel |
| CA2098777A1 (en) | 1992-06-19 | 1993-12-20 | Yukio Fujisawa | Production of human cathepsin and its use |
| JPH0775573A (ja) | 1992-06-19 | 1995-03-20 | Takeda Chem Ind Ltd | ヒトカテプシンの製造法および該酵素含有製剤 |
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| JPH06192124A (ja) | 1992-12-25 | 1994-07-12 | Toray Ind Inc | 血液細胞増加剤 |
| US5353961A (en) | 1993-01-15 | 1994-10-11 | Reseal International Limited Partnership | Dual chamber dispenser |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| WO1994028024A1 (en) | 1993-06-01 | 1994-12-08 | Enzon, Inc. | Carbohydrate-modified polymer conjugates with erythropoietic activity |
| US5354566A (en) | 1993-06-02 | 1994-10-11 | Kraft General Foods, Inc. | Preparation of yeast-leavened dough crusts |
| GB9319103D0 (en) | 1993-09-15 | 1993-11-03 | Unilever Plc | Skin care method & composition |
| US5395326A (en) | 1993-10-20 | 1995-03-07 | Habley Medical Technology Corporation | Pharmaceutical storage and mixing syringe having high pressure assisted discharge |
| US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5919455A (en) | 1993-10-27 | 1999-07-06 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5446090A (en) | 1993-11-12 | 1995-08-29 | Shearwater Polymers, Inc. | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
| PT750672E (pt) | 1994-03-17 | 2002-05-31 | Max Delbrueck Centrum | Sequencias de adn para metaloproteases matriciais, sua preparacao e utilizacao. |
| US5795569A (en) | 1994-03-31 | 1998-08-18 | Amgen Inc. | Mono-pegylated proteins that stimulate megakaryocyte growth and differentiation |
| GEP20002180B (en) | 1994-03-31 | 2000-07-25 | Amgen Inc | Composition and Methods for Stimulating Megakaryocyte Growth and Differentiation |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| US6093563A (en) | 1994-07-08 | 2000-07-25 | Ibex Technologies R And D, Inc. | Chondroitin lyase enzymes |
| US5589171A (en) | 1994-08-22 | 1996-12-31 | Advance Biofactures Of Curacao | Treatment of Dupuytren's disease with collagenase |
| US5496284A (en) | 1994-09-27 | 1996-03-05 | Waldenburg; Ottfried | Dual-chamber syringe & method |
| US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| US6544767B1 (en) * | 1994-10-27 | 2003-04-08 | Axys Pharmaceuticals, Inc. | Cathespin O2 protease |
| DE4445969C1 (de) | 1994-12-22 | 1996-03-14 | Schott Glaswerke | Spritzenzylinder für eine Zweikammer-Fertigspritze, Zweikammer-Fertigspritze und Verfahren zum Herstellen und Füllen derselben |
| US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| US5536499A (en) | 1995-02-24 | 1996-07-16 | Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. | Cosmetic compositions for reducing or preventing signs of cellulite |
| US5523090A (en) | 1995-02-24 | 1996-06-04 | Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. | Skin treatment composition |
| US5747027A (en) | 1995-04-07 | 1998-05-05 | The Regents Of The University Of California | BH55 hyaluronidase |
| US6461378B1 (en) | 1995-05-05 | 2002-10-08 | Thermage, Inc. | Apparatus for smoothing contour irregularities of skin surface |
| US5705364A (en) | 1995-06-06 | 1998-01-06 | Genentech, Inc. | Mammalian cell culture process |
| US5672662A (en) | 1995-07-07 | 1997-09-30 | Shearwater Polymers, Inc. | Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications |
| US5705170A (en) | 1995-10-24 | 1998-01-06 | Plantech International, Inc. | Herbal cellulite treatments |
| US5747322A (en) | 1996-05-09 | 1998-05-05 | The Regents Of The University Of California | Recombinant crab collagenase |
| US5976556A (en) | 1996-06-13 | 1999-11-02 | Active Organics, Inc. | Combination of acid protease enzymes and acidic buffers and uses thereof |
| US5667793A (en) | 1996-08-02 | 1997-09-16 | Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. | Skin care compositions for treating cellulite |
| US5776759A (en) | 1996-09-26 | 1998-07-07 | Incyte Pharmaceuticals, Inc. | Two novel human cathepsin proteins |
| US6214966B1 (en) | 1996-09-26 | 2001-04-10 | Shearwater Corporation | Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution |
| US6193963B1 (en) | 1996-10-17 | 2001-02-27 | The Regents Of The University Of California | Method of treating tumor-bearing patients with human plasma hyaluronidase |
| US6258351B1 (en) | 1996-11-06 | 2001-07-10 | Shearwater Corporation | Delivery of poly(ethylene glycol)-modified molecules from degradable hydrogels |
| US5830741A (en) | 1996-12-06 | 1998-11-03 | Boehringer Mannheim Corporation | Composition for tissue dissociation containing collagenase I and II from clostridium histolyticum and a neutral protease |
| US6086872A (en) | 1997-03-27 | 2000-07-11 | Advance Biofactures Of Curacao, Nv | Amelioration of dupuytren's disease |
| US6071526A (en) | 1997-03-27 | 2000-06-06 | S.W. Patentverwertungs Ges M.B. H. | Cosmetic or cosmetic product for firming and soothing the skin in particular in the case of cellulite |
| US5990237A (en) | 1997-05-21 | 1999-11-23 | Shearwater Polymers, Inc. | Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines |
| US6294350B1 (en) | 1997-06-05 | 2001-09-25 | Dalhousie University | Methods for treating fibroproliferative diseases |
| EP0998572A2 (en) | 1997-07-25 | 2000-05-10 | Du Pont Pharmaceuticals Company | Aggrecan degrading metallo proteases |
| FR2767833B1 (fr) | 1997-08-29 | 2001-03-02 | Oreal | Polypeptide isole de l'epiderme et son utilisation |
| US5971953A (en) | 1998-01-09 | 1999-10-26 | Bachynsky; Nicholas | Dual chamber syringe apparatus |
| US6448369B1 (en) | 1997-11-06 | 2002-09-10 | Shearwater Corporation | Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation |
| US5985263A (en) | 1997-12-19 | 1999-11-16 | Enzon, Inc. | Substantially pure histidine-linked protein polymer conjugates |
| US6153207A (en) | 1998-03-05 | 2000-11-28 | Pugliese; Peter T. | Anti-cellulite pantyhose |
| JP4078032B2 (ja) | 1998-03-12 | 2008-04-23 | ネクター セラピューティックス エイエル，コーポレイション | 近位の反応性基を持つポリ（エチレングリコール）誘導体 |
| KR20010041902A (ko) | 1998-03-16 | 2001-05-25 | 데이비드 엠 모이어 | 포유류의 피부 내의 셀룰라이트를 감소시키는 방법 |
| US6528286B1 (en) | 1998-05-29 | 2003-03-04 | Genentech, Inc. | Mammalian cell culture process for producing glycoproteins |
| CN1314992A (zh) | 1998-07-03 | 2001-09-26 | 奈勒斯菲尔德控制有限公司 | 流体测量的方法和装置 |
| US6031005A (en) | 1998-08-03 | 2000-02-29 | Easterling; W. Jerry | Composition and method for treating Peyronie's disease and related connective tissue disorders |
| US6443914B1 (en) | 1998-08-10 | 2002-09-03 | Lysonix, Inc. | Apparatus and method for preventing and treating cellulite |
| US6420339B1 (en) | 1998-10-14 | 2002-07-16 | Amgen Inc. | Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility |
| US6060474A (en) | 1998-11-05 | 2000-05-09 | New York Society For The Relief Of The Ruptured And Crippled Maintaining The Hospital For Special Surgery | Method for preventing scar tissue formation |
| EP1150699A4 (en) | 1999-02-01 | 2004-06-30 | John Lezdey | TREATMENT OF BLADDER AND GASTROINTESTINAL MASTO CYTOSIS |
| WO2000066139A2 (en) * | 1999-04-29 | 2000-11-09 | Ista Pharmaceuticals, Inc. | Biochemical methods that eliminate corneal scars, opacification and haze |
| US6022539A (en) | 1999-06-03 | 2000-02-08 | Advance Biofactures Of Curacao | Amelioration of peyronie's disease |
| JO2291B1 (en) | 1999-07-02 | 2005-09-12 | اف . هوفمان لاروش ايه جي | Erythropoietin derivatives |
| CZ299516B6 (cs) | 1999-07-02 | 2008-08-20 | F. Hoffmann-La Roche Ag | Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem |
| US6656701B2 (en) | 1999-07-16 | 2003-12-02 | Actim Organics, Inc | Combination of acid protease enzymes and acidic buffers and uses thereof |
| US6461802B1 (en) | 1999-08-02 | 2002-10-08 | Agfa-Gevaert | Adhesive layer for polyester film |
| AU6918700A (en) | 1999-08-20 | 2001-03-19 | Howard Murad | Pharmaceutical compositions and methods for reducing the appearance of cellulite |
| ITMI991894A1 (it) | 1999-09-09 | 2001-03-09 | Carlo Ghisalberti | Acido linoleico coniugato e trigliceride nuovi metodi di sintesi e d'uso |
| US6355243B1 (en) | 1999-11-13 | 2002-03-12 | Bayer Corporation | Method of thrombolysis by local delivery of active plasmin |
| CA2394980C (en) | 1999-12-22 | 2008-05-13 | Shearwater Corporation | Sterically hindered derivatives of water soluble polymers |
| US6413507B1 (en) | 1999-12-23 | 2002-07-02 | Shearwater Corporation | Hydrolytically degradable carbamate derivatives of poly (ethylene glycol) |
| AU2351601A (en) | 1999-12-28 | 2001-07-09 | Asger Lau Dalmose | Dual chamber syringe with a dual function piston |
| US20030212021A1 (en) | 2001-01-25 | 2003-11-13 | Frost Gregory I. | Myeloid colony stimulating factor and uses thereof |
| JP2003534834A (ja) | 2000-01-28 | 2003-11-25 | ノボ ノルディスク アクティーゼルスカブ | 投与量設定リミッター |
| US6602498B2 (en) | 2000-02-22 | 2003-08-05 | Shearwater Corporation | N-maleimidyl polymer derivatives |
| WO2001064919A2 (en) * | 2000-02-28 | 2001-09-07 | Millennium Pharmaceuticals, Inc. | 18036, a novel calpain-like protease and uses thereof |
| US6586398B1 (en) | 2000-04-07 | 2003-07-01 | Amgen, Inc. | Chemically modified novel erythropoietin stimulating protein compositions and methods |
| EP1280531B1 (en) | 2000-05-12 | 2007-01-24 | Novalar Pharmaceuticals, Inc. | Formulation consisting of phentolamine mesylate and the use thereof |
| IL152804A0 (en) | 2000-05-16 | 2003-06-24 | Bolder Biotechnology Inc | Methods for refolding proteins containing free cysteine residues |
| US20020106388A1 (en) | 2000-11-24 | 2002-08-08 | Pugliese Peter T. | Formulation of flavones and isoflavones for treatment of cellulite |
| EP1345628B1 (en) | 2000-12-20 | 2011-04-13 | F. Hoffmann-La Roche AG | Conjugates of erythropoietin (epo) with polyethylene glycol (peg) |
| TWI246524B (en) | 2001-01-19 | 2006-01-01 | Shearwater Corp | Multi-arm block copolymers as drug delivery vehicles |
| WO2002080962A1 (en) * | 2001-04-06 | 2002-10-17 | Santana Cristiano Alberto Ribe | Papaine containing pharmaceutical formulation resp. its use |
| CA2349506C (en) | 2001-06-14 | 2009-12-08 | Duke University | A method for selective expression of therapeutic genes by hyperthermia |
| US20030026794A1 (en) * | 2001-07-31 | 2003-02-06 | Howard Fein | Selective enzyme treatment of skin conditions |
| US6908963B2 (en) | 2001-10-09 | 2005-06-21 | Nektar Therapeutics Al, Corporation | Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith |
| EP1446438A2 (en) | 2001-11-07 | 2004-08-18 | Nektar Therapeutics Al, Corporation | Branched polymers and their conjugates |
| US6972005B2 (en) | 2002-05-10 | 2005-12-06 | Boehm Jr Frank H | Dual chamber syringe and dual lumen needle |
| US6682904B1 (en) | 2002-08-15 | 2004-01-27 | Deliatroph Pharmaceuticals, Inc. | Specific inhibitors of hyaluronidase 2, and methods of identifying and using same |
| KR20040040782A (ko) | 2002-11-08 | 2004-05-13 | 선바이오(주) | 신규한 헥사-암 폴리에틸렌글리콜과 유도체 및 그의합성방법 |
| CA2508948A1 (en) * | 2002-12-16 | 2004-07-15 | Halozyme, Inc. | Human chondroitinase glycoprotein (chasegp), process for preparing the same, and pharmaceutical compositions comprising thereof |
| BRPI0407882B1 (pt) | 2003-02-26 | 2021-07-27 | Nektar Therapeutics | Composição compreendendo conjugados de polímero-porção de fator viii e seu método de fabricação |
| NZ542873A (en) | 2003-03-05 | 2008-07-31 | Halozyme Inc | Soluble, neutral-active hyaluronidase activity glycoprotein (sHASEGP) that is produced with high yield in a mammalian expression system by introducing nucleic acids that lack a narrow region encoding amino acids in the carboxy terminus of the human PH20 cDNA |
| US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| US20090123367A1 (en) | 2003-03-05 | 2009-05-14 | Delfmems | Soluble Glycosaminoglycanases and Methods of Preparing and Using Soluble Glycosaminoglycanases |
| US20060104968A1 (en) * | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
| US7610156B2 (en) | 2003-03-31 | 2009-10-27 | Xencor, Inc. | Methods for rational pegylation of proteins |
| KR100512483B1 (ko) | 2003-05-07 | 2005-09-05 | 선바이오(주) | 신규한 폴리에틸렌글리콜-말레이미드 유도체의 합성방법 |
| EP2644206B1 (en) | 2003-05-23 | 2019-04-03 | Nektar Therapeutics | PEG derivatives containing two PEG chains |
| US20050042213A1 (en) | 2003-08-14 | 2005-02-24 | Insight Biopharmaceuticals Ltd. | Methods and pharmaceutical compositions for modulating heparanase activation and uses thereof |
| US7572613B2 (en) | 2004-06-25 | 2009-08-11 | Klein Jeffrey A | Drug delivery system for accelerated subcutaneous absorption |
| US7854929B2 (en) | 2005-01-21 | 2010-12-21 | The Research Foundation Of State University Of New York | Method for treating lateral epicondylitis using collagenase |
| US20070224184A1 (en) | 2006-02-22 | 2007-09-27 | The Research Foundation Of The State University Of New York | Method for treating cellulite |
| AU2006216544B2 (en) | 2005-02-25 | 2012-04-05 | Onconova Therapeutics, Inc. | Unsaturated sulfides, sulfones, sulfoxides and sulfonamides synthesis |
| CA2612768A1 (en) | 2005-06-30 | 2007-01-11 | Mallinckrodt Inc. | Dual chamber syringe |
| US20070128685A1 (en) | 2005-07-01 | 2007-06-07 | Rodolfo Faudoa | Methods and compositions for cell culture |
| US20070004036A1 (en) | 2005-07-01 | 2007-01-04 | Rodolfo Faudoa | Methods and compositions for keratinocyte culture |
| US20070003541A1 (en) | 2005-07-01 | 2007-01-04 | Rodolfo Faudoa | Methods and compositions for therapeutics |
| US7811560B2 (en) | 2006-01-30 | 2010-10-12 | Auxilium Us Holdings, Llc | Compositions and methods for treating collagen-mediated diseases |
| US20080131500A1 (en) | 2006-12-04 | 2008-06-05 | The Board Of Regents Of The University Of Texas System | Methods and compositions for rapid inactivation of proteins |
| SI4269578T1 (sl) | 2008-03-06 | 2024-07-31 | Halozyme, Inc. | Sestava topne hialuronidaze |
| TWI395593B (zh) | 2008-03-06 | 2013-05-11 | Halozyme Inc | 可活化的基質降解酵素之活體內暫時性控制 |
| KR20130116386A (ko) | 2008-04-14 | 2013-10-23 | 할로자임, 아이엔씨 | 히알루로난 관련 질환 및 상태 치료용 변형된 히알루로니다제 및 그 용도 |
| EA022752B1 (ru) | 2008-12-09 | 2016-02-29 | Галозим, Инк. | Длинные растворимые полипептиды рн20 и их использование |
| EP2403523A1 (en) | 2009-03-06 | 2012-01-11 | Halozyme, Inc. | Temperature sensitive mutants of matrix metalloprotease 1 und uses thereof |
| CN102369296A (zh) | 2009-03-09 | 2012-03-07 | 生物蛋白有限公司 | Mirac蛋白 |
| MX349622B (es) | 2010-09-08 | 2017-08-07 | Halozyme Inc | Metodos para evaluar e identificar o evolucionar proteinas terapeuticas condicionalmente activas. |
| AU2013229786B2 (en) | 2012-03-08 | 2017-06-22 | Halozyme, Inc. | Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof |
-
2009
- 2009-03-05 TW TW098107084A patent/TWI395593B/zh not_active IP Right Cessation
- 2009-03-06 AU AU2009220094A patent/AU2009220094B2/en not_active Ceased
- 2009-03-06 MX MX2010009806A patent/MX2010009806A/es active IP Right Grant
- 2009-03-06 KR KR1020107022203A patent/KR20100135779A/ko not_active Abandoned
- 2009-03-06 CL CL2009000541A patent/CL2009000541A1/es unknown
- 2009-03-06 ES ES09716286.1T patent/ES2586765T3/es active Active
- 2009-03-06 KR KR1020157004822A patent/KR101647933B1/ko not_active Expired - Fee Related
- 2009-03-06 CA CA2718549A patent/CA2718549C/en not_active Expired - Fee Related
- 2009-03-06 KR KR1020137024682A patent/KR20130106893A/ko not_active Ceased
- 2009-03-06 EP EP09716286.1A patent/EP2274004B1/en active Active
- 2009-03-06 WO PCT/US2009/001486 patent/WO2009111083A2/en not_active Ceased
- 2009-03-06 BR BRPI0909622A patent/BRPI0909622A2/pt not_active IP Right Cessation
- 2009-03-06 US US12/381,063 patent/US9833498B2/en active Active
- 2009-03-06 JP JP2010549679A patent/JP5709531B2/ja not_active Expired - Fee Related
- 2009-03-06 AR ARP090100823A patent/AR076627A1/es unknown
-
2010
- 2010-07-29 IL IL207293A patent/IL207293A/en not_active IP Right Cessation
- 2010-09-08 CO CO10111097A patent/CO6331294A2/es not_active Application Discontinuation
-
2013
- 2013-07-18 CL CL2013002070A patent/CL2013002070A1/es unknown
- 2013-10-02 JP JP2013207338A patent/JP2014043449A/ja active Pending
-
2014
- 2014-04-02 US US14/243,805 patent/US9775889B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| TWI395593B (zh) | 2013-05-11 |
| KR20100135779A (ko) | 2010-12-27 |
| IL207293A (en) | 2016-12-29 |
| JP2014043449A (ja) | 2014-03-13 |
| EP2274004A2 (en) | 2011-01-19 |
| US20140271609A1 (en) | 2014-09-18 |
| CL2013002070A1 (es) | 2013-11-15 |
| KR101647933B1 (ko) | 2016-08-11 |
| KR20130106893A (ko) | 2013-09-30 |
| IL207293A0 (en) | 2010-12-30 |
| CA2718549A1 (en) | 2009-09-11 |
| WO2009111083A2 (en) | 2009-09-11 |
| BRPI0909622A2 (pt) | 2019-09-24 |
| CL2009000541A1 (es) | 2009-10-09 |
| ES2586765T3 (es) | 2016-10-18 |
| WO2009111083A3 (en) | 2010-03-25 |
| AU2009220094A1 (en) | 2009-09-11 |
| JP2011517318A (ja) | 2011-06-02 |
| MX2010009806A (es) | 2010-11-30 |
| CO6331294A2 (es) | 2011-10-20 |
| KR20160073346A (ko) | 2016-06-24 |
| EP2274004B1 (en) | 2016-06-01 |
| US9833498B2 (en) | 2017-12-05 |
| HK1150554A1 (zh) | 2012-01-06 |
| AU2009220094B2 (en) | 2013-11-07 |
| AR076627A1 (es) | 2011-06-29 |
| TW200944227A (en) | 2009-11-01 |
| JP5709531B2 (ja) | 2015-04-30 |
| US9775889B2 (en) | 2017-10-03 |
| US20100003237A1 (en) | 2010-01-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2718549C (en) | In vivo temporal control of activatable matrix-degrading enzymes | |
| US20110229451A2 (en) | Temperature sensitive mutants of matrix metalloproteases and uses thereof | |
| US20250222078A1 (en) | Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions | |
| JP2020172494A (ja) | ヒアルロナン分解酵素の脂質製剤 | |
| AU2013202011C1 (en) | In vivo temporal control of activatable matrix-degrading enzymes | |
| HK1150554B (en) | In vivo temporal control of activ at able matrix- degrading enzymes | |
| US20150196625A9 (en) | Metal Sensitive Mutants of Matrix Metalloproteases and uses thereof | |
| AU2013201899A1 (en) | Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions | |
| HK1234339A1 (en) | Modified hyaluronidases for use in treating hyaluronan-associated diseases and conditions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20180306 |